Morphologic and Microvascular Differences Between Macular Neovascularization With and Without Subretinal Fibrosis.
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
27
1
2022
Statut:
ppublish
Résumé
To evaluate morphologic and microvascular differences between eyes with and without subretinal fibrosis (SF) caused by neovascular age-related macular degeneration (nAMD). Patients with nAMD with a minimum history of 12 months of anti-VEGF treatment were prospectively included in this cross-sectional study. Patients were imaged using standard imaging, swept-source optical coherence tomography angiography for quantitative microvascular analysis and polarization-sensitive OCT as an ancillary method for automated SF segmentation. The presence of reticular pseudodrusen, hyperreflective foci (HRF), and outer retinal tubulation (ORT) were also evaluated. Sixty eyes of 60 participants (37 female) with nAMD and a mean 3.1 (±2.7)-year history of anti-VEGF treatment were included, 20 (33%) of which were diagnosed with SF. Eyes with SF had a higher prevalence of ORT (P < 0.001) and a lower prevalence of HRF (P = 0.004) than eyes without SF. Fifty eyes were analyzed quantitatively for microvascular biomarkers. Eyes with SF had a larger greatest vascular caliber (P = 0.001) and greatest linear diameter (P = 0.042), a larger microvascular neovascularization (MNV) area (P = 0.026), larger vessel area (P = 0.037), higher number of vessel junctions (P = 0.025), longer total vessel length (P = 0.027), higher number of vessel endpoints (P = 0.007), and higher endpoint density (P = 0.047). This multimodal imaging approach demonstrated in vivo microvascular and morphological differences in eyes with and without SF. Eyes with SF tend to have larger MNV lesions with thicker vessels and are often associated with the presence of ORT. This study points out imaging biomarkers in patients with SF, which may help identifying high-risk patients.
Identifiants
pubmed: 34851359
pii: 2778126
doi: 10.1167/tvst.10.14.1
pmc: PMC8648059
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1Subventions
Organisme : Austrian Science Fund FWF
ID : KLI 749
Pays : Austria
Références
Invest Ophthalmol Vis Sci. 2015 May;56(5):3253-68
pubmed: 25813989
Biomed Opt Express. 2013 Dec 06;5(1):106-22
pubmed: 24466480
Exp Eye Res. 2019 Jul;184:286-295
pubmed: 31029789
J Mol Med (Berl). 2015 Jul;93(7):749-58
pubmed: 25947075
Clin Ophthalmol. 2018 Nov 05;12:2267-2276
pubmed: 30464388
Ophthalmology. 2011 Apr;118(4):687-93
pubmed: 21093923
Invest Ophthalmol Vis Sci. 2019 Feb 1;60(2):528-537
pubmed: 30707754
Br J Ophthalmol. 2020 Jan;104(1):47-52
pubmed: 31000509
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):304-311
pubmed: 30657855
Ophthalmol Retina. 2019 Dec;3(12):1045-1055
pubmed: 31444144
Clin Cancer Res. 2019 Sep 1;25(17):5242-5249
pubmed: 31175092
Retina. 2017 Feb;37(2):222-233
pubmed: 27627752
Arch Dermatol Res. 2014 Jan;306(1):1-9
pubmed: 24113905
Ophthalmology. 2010 Sep;117(9):1775-81
pubmed: 20472293
Retina. 2017 Aug;37(8):1492-1498
pubmed: 27997513
Exp Eye Res. 2016 Jan;142:19-25
pubmed: 25773985
PLoS One. 2017 May 10;12(5):e0177059
pubmed: 28489918
Eur J Ophthalmol. 2021 May;31(3):1192-1200
pubmed: 32450717
Ther Adv Ophthalmol. 2019 Apr 03;11:2515841419840249
pubmed: 30984909
Am J Ophthalmol. 2015 Jul;160(1):6-16
pubmed: 25887628
Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1699-705
pubmed: 27064389
Am J Ophthalmol. 2020 Feb;210:116-124
pubmed: 31606444
Am J Ophthalmol. 2015 Aug;160(2):335-344.e1
pubmed: 25982973
Retina. 2015 Nov;35(11):2252-9
pubmed: 26457400
Ophthalmology. 2020 May;127(5):616-636
pubmed: 31864668
Ophthalmology. 2015 Sep;122(9):1846-53.e5
pubmed: 26143666
Transl Vis Sci Technol. 2020 Mar 16;9(4):13
pubmed: 32818100
Ophthalmol Retina. 2018 May;2(5):451-461
pubmed: 31047325
Opt Express. 2008 Oct 13;16(21):16410-22
pubmed: 18852747
Am J Ophthalmol. 2020 May;213:109-119
pubmed: 31954711
Ophthalmology. 2013 Nov;120(11):2292-9
pubmed: 23642856
Prog Retin Eye Res. 2011 Nov;30(6):431-51
pubmed: 21729763
Br J Ophthalmol. 2003 May;87(5):609-14
pubmed: 12714405
Mol Ther Nucleic Acids. 2019 Sep 6;17:113-125
pubmed: 31254924
Biomed Opt Express. 2021 Jun 23;12(7):4380-4400
pubmed: 34457420
Transl Vis Sci Technol. 2019 May 2;8(3):6
pubmed: 31106033
Ophthalmology. 2018 Jul;125(7):1037-1046
pubmed: 29454660
Ophthalmologica. 2018;240(2):90-98
pubmed: 29739007
Retina. 2015 Jul;35(7):1339-50
pubmed: 25635579
Arch Ophthalmol. 2009 Dec;127(12):1596-602
pubmed: 20008714
Clin Exp Ophthalmol. 2020 Jul;48(5):636-643
pubmed: 32112667
Ophthalmology. 2014 Mar;121(3):656-66
pubmed: 24314839
Br J Ophthalmol. 2017 Oct;101(10):1361-1366
pubmed: 28270492
PLoS One. 2011;6(11):e27385
pubmed: 22110636
Prog Retin Eye Res. 2018 May;64:1-55
pubmed: 29229445
Am J Ophthalmol. 2015 May;159(5):915-24.e2
pubmed: 25640411
Ophthalmologica. 2019;242(3):178-186
pubmed: 31195396
Am J Ophthalmol. 2013 Jul;156(1):116-124.e1
pubmed: 23664150
Biomed Opt Express. 2012 Jul 1;3(7):1670-83
pubmed: 22808437